Yichang Renfu Pharmaceutical's valaciclovir hydrochloride tablets have passed the consistency evaluation for a new specification.
Time：
2025-04-21
Recently, Yichang Renfu Pharmaceutical Co., Ltd. received an Approval Notice for Supplemental Application of Drugs from the National Medical Products Administration (NMPA), approving the addition of a 0.5g specification for its valacyclovir hydrochloride tablets. This specification has also passed the consistency evaluation of quality and efficacy of generic drugs.
Recently, Yichang Renfu Pharmaceutical Co., Ltd. received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, approving the addition of a 0.5g specification for its Valacyclovir Hydrochloride Tablets, and this specification has passed the consistency evaluation of quality and efficacy of generic drugs.
Valacyclovir Hydrochloride Tablets are indicated for the treatment of herpes zoster, herpes simplex virus infections, and the prevention (suppression) of recurrent herpes simplex virus infections. Valacyclovir is a prodrug of the antiviral drug acyclovir. After oral administration, it is rapidly absorbed and rapidly converted to acyclovir in the body, thereby exerting its therapeutic effect.
Yichang Renfu Pharmaceutical Co., Ltd.'s Valacyclovir Hydrochloride Tablets were approved in 2009 with a 0.15g specification. The addition of this new specification and the passing of the consistency evaluation provide patients with a wider range of treatment options.
Tags:
Related News
ABOUT US
CONTACT
Add：66 Tianjiahe Avenue, Baiyang Town, Baiyang,Industrial Park, High-tech Zone,Yichang City, Hubei Province, China.
Tel：+86-717-4065884 +86-717-4065888
E-mail：yctr@renfu.com.cn
Copyright © 2024 YICHANG TIANRUI BIOPHARM CO., LTD All Rights Reserved.